SWISS RE FULL-YEAR Consensus
» SWISS RE
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Unternehmen
Bundesrat eröffnet Vernehmlassung zum Informationsaustausch in Sachen OECD-Mindestbesteuerung
» Report
Bundesrat streicht EU per 1. Mai 2025 von der Börsenschutz-Liste
» Report
BIOVERSYS LAUNCHES IPO ON THE SIX SWISS EXCHANGE AND SETS IPO PRICE AT CHF 36.00 PER SHARE
» Report
Arbonia AG: Antitrust approval of the EU Commission obtained for the sale of the Climate Division
» Report
Arbonia AG: Kartellrechtliche Genehmigung der EU-Kommission für Verkauf der Division Climate liegt vor
» Report
Change to the Roche Enlarged Corporate Executive Committee
» Report
Adecco Groups Partners with Bullhorn to Drive AI Powered Recruitment Innovation as Part of its Global AI Strategy
» ADECCO
Interroll Holding AG: Good profitability in a difficult economic environment
» Report
Avolta Capital Markets Day 2025 - Save The Date
» Report
Rieter – Significant Increase in Order Intake in Financial Year 2024 Ad-hoc announcement pursuant to Art. 53 LR
» Report
Rieter – deutliche Steigerung des Bestellungseingangs im Geschäftsjahr 2024 Ad hoc-Mitteilung gemäss Art. 53 KR
» Report
Lonza Group AG: Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin
» Report
Lonza Group AG: Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29.0% Kern-EBITDA-Marge
» Report
Logitech - Third Quarter 2025
» Logitech
Logitech - Logitech Announces Fourth Consecutive Quarter of Sales Growth
» Report
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
» Report
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
» Report
Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus
» Report
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
» Report
